|
Cancer Type
|
# of SRGsa
|
DriverDBV3
|
|---|
|
Mutationb
|
CNV
|
Methylation
|
|---|
|
Log-Rank Test
|
|
KIRC
|
7770
|
46.9%
|
(340/725) **
|
0%
|
(0/3)
|
50%
|
(6/12)
|
|
LGG
|
6691
|
32.5%
|
(570/1752)
|
82.2%
|
(37/45) ***
|
–
| |
|
ACC
|
5243
|
19.7%
|
(74/375)
|
32.3%
|
(40/124)
|
–
| |
|
UVM
|
3765
|
25%
|
(9/36)
|
62%
|
(75/121) ***
|
–
| |
|
LIHC
|
2359
|
9.5%
|
(106/1113)
|
9.6%
|
(8/83)
|
6.6%
|
(12/181)
|
|
PRAD
|
1538
|
5.1%
|
(58/1141)
|
23.5%
|
(4/17)
|
4.4%
|
(3/68)
|
|
MESO
|
586
|
2.5%
|
(1/40)
|
0%
|
(0/1)
|
–
| |
|
PAAD
|
443
|
1.6%
|
(16/971)
|
0%
|
(0/2)
|
16%
|
(4/25)**
|
|
KIRP
|
238
|
1.9%
|
(12/631)
|
1.1%
|
(1/87)
|
2.2%
|
(5/224)
|
|
BLCA
|
39
|
0.2%
|
(6/2404)
|
0%
|
(0/104)
|
0%
|
(0/443)
|
|
CESC
|
35
|
0.2%
|
(4/1815)
|
0%
|
(0/52)
|
–
| |
|
LAML
|
29
|
0%
|
(0/413)
|
0%
|
(0/3)
|
–
| |
|
HNSC
|
18
|
0%
|
(0/1914)
|
1%
|
(1/103)
|
0%
|
(0/89)
|
|
STAD
|
10
|
0.1%
|
(4/3695)
|
0%
|
(0/86)
|
–
| |
|
LUAD
|
8
|
0%
|
(1/2903)
|
0%
|
(0/37)
|
0%
|
(0/18)
|
|
SKCM
|
1
|
0%
|
(0/4559)
|
0%
|
(0/18)
|
–
| |
|
Cox Regression
|
|
KIRC
|
7091
|
38.3%
|
(278/725)
|
0%
|
(0/3)
|
50%
|
(6/12)
|
|
ACC
|
6467
|
25.9%
|
(97/375)
|
43.5%
|
(54/124)
|
–
| |
|
UVM
|
5600
|
33.3%
|
(12/36)
|
84.3%
|
(102/121) ***
|
–
| |
|
LGG
|
5418
|
27.2%
|
(476/1752)
|
42.2%
|
(19/45) ***
|
–
| |
|
PAAD
|
4287
|
21.2%
|
(206/971)
|
0%
|
(0/2)
|
36%
|
(9/25)*
|
|
LIHC
|
2384
|
10%
|
(111/1113)
|
8.4%
|
(7/83)
|
9.9%
|
(18/181)
|
|
PRAD
|
2068
|
8.1%
|
(92/1141)
|
35.3%
|
(6/17) *
|
5.9%
|
(4/68)
|
|
MESO
|
728
|
2.5%
|
(1/40)
|
0%
|
(0/1)
|
–
| |
|
KIRP
|
592
|
2.4%
|
(15/631)
|
2.3%
|
(2/87)
|
1.8%
|
(4/224)
|
|
BLCA
|
442
|
2.7%
|
(64/2404)
|
1%
|
(1/104)
|
1.6%
|
(7/443)
|
|
KICH
|
407
|
3.7%
|
(2/54)
|
–
| |
–
| |
|
CESC
|
230
|
1.4%
|
(25/1815)
|
0%
|
(0/52)
|
–
| |
|
HNSC
|
204
|
0.9%
|
(17/1914)
|
1.9%
|
(2/103)
|
0%
|
(0/89)
|
|
LAML
|
158
|
0.7%
|
(3/413)
|
0%
|
(0/3)
|
–
| |
|
LUAD
|
71
|
0.4%
|
(12/2903)
|
5.4%
|
(2/37) **
|
0%
|
(0/18)
|
|
PCPG
|
64
|
2%
|
(1/49)
|
0%
|
(0/5)
|
–
| |
|
BRCA
|
24
|
0.1%
|
(2/2162)
|
0%
|
(0/220)
|
0%
|
(0/36)
|
|
UCEC
|
5
|
0%
|
(0/6669)
|
0%
|
(0/76)
|
–
| |
|
STAD
|
3
|
0%
|
(1/3695)
|
0%
|
(0/86)
|
–
| |
|
SARC
|
2
|
0%
|
(0/543)
|
0%
|
(0/104)
|
–
| |
|
THCA
|
2
|
0%
|
(0/192)
|
0%
|
(0/3)
|
0%
|
(0/201)
|
- Note: Fisher’s exact test of SRGs and cancer driver genes; *p < 0.05, **p < 0.01, ***p < 0.001, one-tailed. The first number in the parentheses indicates the count of overlapping genes between SRGs and cancer driver genes, and the second number indicates total driver genes that are also applicable genes in specified cancer
- - Not available; no driver genes were described in those cancer types
- aSRGs for both models are defined as FDR < 0.05
- bMutation-based driver genes were merged based on 14 tools summarized by DriverDBV3
